期刊文献+

血浆巨噬细胞移动抑制因子与2型糖尿病大血管病变的关系 被引量:8

Plasma macrophage migration ingibitory factor consentration in type 2 diabetic patients with vascular disease
下载PDF
导出
摘要 目的探讨血浆巨噬细胞移动抑制因子(macrophage migration inhibitory factor,MIF)与糖尿病大血管病变的关系。方法检测87例大血管病变患者的血浆MIF及高级糖基化终产物受体(receptor of advanced glycation endproducts,RAGE),并分别分析血浆MIF与RAGE、颈-股动脉脉搏波传导速度(carotidfe moral pulse wave velocity,cfPWV)的相关性。结果糖尿病合并大血管病变患者的血浆MIF浓度显著升高;相关分析显示,糖尿病合并大血管病变患者血浆MIF与RAGE呈正相关(r=0.357,P=0.035),与cfPWV呈负相关(r=-0.293,P=0.042)。结论血浆MIF浓度升高与糖尿病合并大血管病变密切相关,检测糖尿病合并大血管患者的血浆MIF浓度将有助于早期诊断糖尿病大血管病变。 Objectives To determine whether plasma macrophage migration inhibitory factor (MIF) concentration in type 2 diabetes mellitus is related to diabetic macrovascular remodeling. Methods The plasma MIF concentration and receptor of advanced glycation endproducts (RAGE) concentration of 87 macroangiopathy patients were detected. The correlations of the MIF concentration and the carotid inteima-media thickness (IMT) were analyzed. The correlations of the MIF concentration and the carotid-femoral pulse wave velocity (cfPWV) were also measured. Results The concentration of MIF, RAGE in diabetes group was higher than those in diabetes only group and coronary artery disease only group. There was a significant correlation between MIF concentrations and RAGE (r = 0.393, P = 0.030), MIF concentration and cfPWV were negative correlation (r = -0.293, P = 0.042). Conclusions Increased plasma MIF concentrations are related to diabetic macro vascular remodeling. MIF plays a key role in type 2 diabetes with macrovascular remodeling.
出处 《岭南心血管病杂志》 2009年第1期44-46,共3页 South China Journal of Cardiovascular Diseases
关键词 巨噬细胞游走抑制因子 糖基化终产物 高级 糖尿病 2型 血管疾病 macrophage migration inhibitory factor advanced glycation end products type 2 diabetes mellitus cardiovascular disease
  • 相关文献

参考文献7

  • 1YAN S, RAMASAMY R, NAKA Y, et al. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond [J ]. Circ Res, 2003, 93 (10): 1159-1169.
  • 2YABUNAKA N, NISHIHIRA J, MIZUE Y, et al. Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes[J]. Diabetes Care, 2002, 23(2) : 256-258.
  • 3AMERICAN DIABETES ASSOCIATION. Standards of medical care in diabetes-2008 [J]. Diabetes Care, 2008, 31 (suppl 1) : s12-s54.
  • 4RIDKER P M, RIFAI N, ROSE L, et al. Comparison of C- reactive protein and low-density lipopmtein cholesterol levels in the prediction of first cadiovascular events [J ]. N Eng J Med, 2002, 347 (20): 1557-1564.
  • 5HERDER C, KOBL H, KOENIG W, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the finnish diabetes prevention study [ J ]. Diabetes, 2006, 55 (8): 2340-2346.
  • 6HERDER C, KOLB H, KOENIG W, et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4) [J]. Diabetes Care, 2006, 29 (2): 368-371.
  • 7HERDER C, KLOPP N, BAUMERT J, et al. Effect of macrophage migration inhibitory factor (MlF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002[J]. Diabetologia, 2008, 51 (2): 276-284.

同被引文献96

引证文献8

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部